Abbott: Three Supercycles, Mispriced At A 10-Year Low
This investment analysis argues that Abbott Laboratories (ABT) is significantly undervalued, trading at a decade-low forward earnings multiple of 17.7x despite strong fundamentals, including 13.2% growth in its Medical Devices segment during Q1 2026 and a 54-year consecutive dividend streak. The author identifies three underappreciated catalysts likely to drive substantial earnings per share growth by 2028–2029: synergies from the Exact Sciences acquisition, expansion of Continuous Glucose Monitoring (CGM) reimbursement by the Centers for Medicare & Medicaid Services (CMS), and margin recovery in the Nutrition division. These factors are projected to add $1.27–$1.73 to incremental EPS. The article contends that consensus estimates underestimate Abbott’s commercial leverage and distribution synergies, resulting in asymmetric upside potential not currently reflected in market models. Consequently, the analyst assigns a BUY rating to the stock, setting a 12-month price target of $126 and estimating a multi-year intrinsic value exceeding $150. This valuation is supported by the company’s robust cash flow generation and consistent dividend growth, positioning Abbott as an attractive opportunity for investors seeking long-term value in the healthcare sector amidst current market mispricing.
Wire timeline
Abbott: Three Supercycles, Mispriced At A 10-Year Low
This investment analysis argues that Abbott Laboratories (ABT) is significantly undervalued, trading at a decade-low forward earnings multiple of 17.7x despite strong fundamentals, including 13.2% growth in its Medical Devices segment during Q1 2026 and a 54-year consecutive dividend streak. The author identifies three underappreciated catalysts likely to drive substantial earnings per share growth by 2028–2029: synergies from the Exact Sciences acquisition, expansion of Continuous Glucose Monitoring (CGM) reimbursement by the Centers for Medicare & Medicaid Services (CMS), and margin recovery in the Nutrition division. These factors are projected to add $1.27–$1.73 to incremental EPS. The article contends that consensus estimates underestimate Abbott’s commercial leverage and distribution synergies, resulting in asymmetric upside potential not currently reflected in market models. Consequently, the analyst assigns a BUY rating to the stock, setting a 12-month price target of $126 and estimating a multi-year intrinsic value exceeding $150. This valuation is supported by the company’s robust cash flow generation and consistent dividend growth, positioning Abbott as an attractive opportunity for investors seeking long-term value in the healthcare sector amidst current market mispricing.
All Articles on Seeking Alpha